Open AccessEfficacy and Safety of Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: 52-Week Results
Author(s) -
Yoshinori Umezawa,
Akihiko Asahina,
Shinichi Imafuku,
Yayoi Tada,
Shigetoshi Sano,
Akimichi Morita,
Shinya Sakurai,
Naoki Hoshii,
Nicola Tilt,
Hidemi Nakagawa
Publication year - 2021
Publication title -
dermatology and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.181
H-Index - 27
eISSN - 2193-8210
pISSN - 2190-9172
DOI - 10.1007/s13555-021-00520-0
Subject(s) - certolizumab pegol , medicine , psoriasis area and severity index , plaque psoriasis , dermatology life quality index , placebo , psoriasis , surgery , dermatology , infliximab , tumor necrosis factor alpha , alternative medicine , pathology
Certolizumab pegol (CZP), an Fc-free, PEGylated anti-tumour necrosis factor biologic, dosed at 400 mg every 2 weeks (Q2W) and 200 mg Q2W over 16 weeks, resulted in improvements in Japanese patients with moderate to severe plaque psoriasis (PSO); no new safety signals were identified. We present 52-week efficacy and safety results.